Cures of leukemia with aggressive postremission treatment: an update of timed sequential therapy (Ac-D-Ac).
A cure rate can be obtained with intensive cytoreductive treatment given to a subset of patients with acute myelocytic leukemia in bone marrow remission. This report updates our experience with postremission timed sequential therapy using cytarabine and daunorubicin (Ac-D-Ac) and compares it with other brief, aggressive strategies including bone marrow transplantation. The median disease-free survival (DFS) of all patients treated in remission is 2.5 years with a greater than 40% probability of DFS at 8 years. These results are similar to those achieved with bone marrow-ablative and other intensive but nonablative treatment plans.
Burke
P J
PJ
Johns Hopkins Oncology Center, Baltimore, MD 21205.
Karp
J E
JE
Geller
R B
RB
Vaughan
W P
WP
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003561:Cytarabine / Q000008:administration & dosage*; D003630:Daunorubicin / Q000008:administration & dosage*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality
D003561:Cytarabine; D003630:Daunorubicin